Dáil Éireann Debate, Tuesday - 23 June 2020
416. Deputy Michael Moynihan asked the Minister for Health the status of a decision on the reimbursement for the drug osimertinib for treatment of advanced lung cancer; and if he will make a statement on the matter. [11773/20]
Amharc ar fhreagra459. Deputy Thomas Byrne asked the Minister for Health the status of the reimbursement of osimertinib. [12087/20]
Amharc ar fhreagra532. Deputy Darren O'Rourke asked the Minister for Health when Tagrisso will be available to patients under the general medical scheme; and if he will make a statement on the matter. [12457/20]
Amharc ar fhreagraI propose to take Questions Nos. 416, 459 and 532 together.
The HSE has statutory responsibility for medicine pricing and reimbursement decisions, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013. The Act specifies the criteria to be applied in the making of reimbursement decisions which include the clinical and cost effectiveness of the product, the opportunity cost and the impact on resources that are available to the HSE.
I can advise the Deputy that the HSE has approved the application for reimbursement of Osimertinib (Tagrisso) for non small cell lung cancer, the specific recommendation is for second-line use for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive non small cell lung cancer.
Reimbursement will commence from 1 July 2020.
